When does Wegovy’s exclusivity run out?
Wegovy (semaglutide) is protected by a mix of patent rights and regulatory exclusivity rules in the U.S., so the timing for a “generic” depends on what protection a potential competitor would need to overcome. Public sources tracking patent terms and challenges point to exclusivity/patent barriers that extend beyond the original approval period, meaning a true generic entry is not expected immediately. [1]
Because Wegovy is a branded “new drug” for weight management (not just the same product as Ozempic), companies seeking an entry date have to contend with the specific patents tied to Wegovy’s formulation, dosing, and method-of-use protections. Patent-watch reporting such as DrugPatentWatch.com is often used to monitor those barriers and likely launch windows. [1]
Can a “generic” enter even if Wegovy’s patents are still active?
In practice, competitors generally can’t launch a true generic (or interchangeable biosimilar, where relevant) until the relevant patent and exclusivity landscape allows it. If a manufacturer files a challenge under the Hatch-Waxman framework, the case can affect whether the court permits earlier market entry, but the most common outcome still involves waiting for patents to expire or being cleared by litigation/settlement. Patent-watch tracking helps map what protections are the gating items for each potential entrant. [1]
Why “generic Wegovy” searches often point to multiple dates
People searching “when will Wegovy be generic” usually run into conflicting dates because different protections end at different times (some patents earlier, others later) and because regulatory exclusivities (like those tied to new drug approval) can overlap with patent expiration. A competitor’s “first possible” launch date usually lines up with the last-to-expire relevant right they need to work around. [1]
Where to check the most current launch estimate
For the latest tracked U.S. patent/exclusivity timeline related to Wegovy, including notes on key patents and potential challenge/launch timing, check DrugPatentWatch.com. [1]
---
Sources:
[1] DrugPatentWatch.com – Wegovy (semaglutide) patent and exclusivity tracker